3 March 2021

Bioengineering company CN Bio announced it has received a grant from Innovate UK, to develop human-relevant single and multi-organ models to advance research on the SARS-CoV-2 virus, which causes Covid-19. The funding will allow CN Bio to develop and test advanced cell culture models that represent different parts of the lung and subsequently link these models to other organs, such as the liver and gut, to guide the development of novel Covid-19 therapeutics.

The first doses of AstraZeneca/University of Oxford‘s Covid-19 vaccine have arrived in many low and middle-income countries across the world through the COVAX initiative. Reports suggests that supply to 142 countries is currently underway, with a majority of doses being manufactured by AstraZeneca and its licence partner the Serum Institute of India. The first COVAX shipments were dispatched to Ghana and Cote D’Ivoire last week, and doses are expected to arrive soon in the Philippines, Fiji, Mongolia, Indonesia, and Moldova.

The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) will provide Merck with $268.8m in funding to enhance the existing manufacturing facilities for Covid-19 vaccines and medicines production. Merck will also support the manufacturing and supply of Johnson & Johnson’s Covid-19 vaccine using its facilities in the US to formulate and fill vials of the vaccine.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.